Abbildung 2: Telmisartan - Placebo - Verträglichkeit
Telmisartan has been evaluated for safety in 27 studies in a total of 5363 patients with essential hypertension, including 2921 patients treated for up to 6 months, 888 patients treated between 6 and 12 months, and 1554 patients treated for 1 year or more.1 Adverse events were typically mild and transient in nature. In placebo-controlled trials that included 1758 patients treated with doses ranging from 20 mg to 160 mg (1344 patients received telmisartan monotherapy, 414 received telmisartan/HCTZ combination), the incidence of adverse events was comparable to that of placebo.1 Headache was the most frequently reported adverse event (7.1% in telmisartan-treated patients vs 15.1% in the placebo group).1 Data on file. Boehringer Ingelheim GmbH.